Lycera’s double-action immuno-oncology drug starts trials

Lycera has pushed the first of its RORgamma agonist immuno-oncology drugs—partnered with Celgene—into early-stage clinical testing.

FDA Grants Bayer (BAY) Priority Review For Stivarga (Regorafenib) For The Second-Line Systemic Treatment...

Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted priority review status for the supplemental New Drug Application (sNDA) for Stivarga® (regorafenib) tablets for the second-line systemic treatment of patients with hepatocellular carcinoma (HCC) in the U.S.

FDA Grants Accelerated Approval to New Treatment for Advanced Ovarian Cancer

The U.S. Food and Drug Administration on December 19 granted accelerated approval to Rubraca (rucaparib) to treat women with a certain type of ovarian cancer. Rubraca is approved for women with advanced...

Hutchison China MediTech (Chi-Med) Release: Biopharma Initiates A Phase II Study Of Sulfatinib In...

Most biotechs start life with little money, one or several early-stage assets, a handful of employees and big dreams but face an uphill struggle to stay alive, let alone get to...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

Life Science Leaders Celebrate Global Partnerships During WuXi Global Forum 2018

More than 2,000 life science industry insiders around the globe participated in the WuXi Global Forum on Jan. 9, 2018 during the annual J.P....

WuXi Global Forum 2018